ADC & Bioconjugate East Asia aims to unite leading experts to drive innovation in antibody-drug conjugates (ADCs) and foster collaboration across the biopharmaceutical landscape.

Set to launch in 2025, ADC & Bioconjugate East Asia (ADCBio) will gather top professionals and innovators from South Korea, Japan, China, and Taiwan to share insights on the most recent advancements in ADC technology and bioconjugation methods. As the region progresses in targeted therapy innovations, ADCBio will act as a vital hub for collaboration among biopharma companies, contract manufacturers, regulatory bodies, and academic institutions.

The conference is set to explore revolutionary ADC development and bioconjugation approaches, concentrating on improving efficacy, scalability, and manufacturability. Important topics will include enhancements in preclinical research, process efficiency, CMC factors, and strategies for gaining market access. ADCBio aims to bridge the gap between scientific developments and their clinical and commercial applications, offering valuable information about the changing ADC sector.

As part of the larger Biologics World Korea 2025, ADCBio will also be held alongside Biologics Manufacturing Korea 2025 and CGT East Asia 2025, providing a unique opportunity for networking, knowledge exchange, and expanding business prospects. Whether attendees are looking for insights into regulations, investment possibilities, or establishing strategic alliances, ADCBio is the key gathering to engage with significant players in the ADC field across East Asia.